mezagitamab + lenalidomide + dexamethasone

This is a combination regimen composed of mezagitamab, lenalidomide, and dexamethasone: - **Mezagitamab** is a monoclonal antibody targeting CD38, designed for the treatment of multiple myeloma and other hematological malignancies through immune-mediated destruction of CD38-expressing tumor cells[5]. - **Lenalidomide** is an immunomodulatory small molecule acting on multiple myeloma cells, approved for use in combination with dexamethasone in various lines of therapy, primarily through modulation of the cereblon E3 ubiquitin ligase complex and influencing immune response[1][2][4]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid used as an anti-inflammatory and immunosuppressant, commonly given orally in myeloma regimens. This combination is in investigation for relapsed/refractory multiple myeloma[5].

Brand names

Revlimid (lenalidomide)Decadron (dexamethasone)